CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Cash flows from operating activities:
Net loss	$ (118,929)	$ (96,483)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash interest expense on liability related to sale of future royalties	12,856
Non-cash royalty revenue related to sale of future royalties	(6,895)
Stock-based compensation	12,015	14,501
Depreciation and amortization	10,595	11,424
Impairment of long-lived assets	1,675
Other non-cash transactions	641	967
Changes in operating assets and liabilities:
Accounts receivable	1,027	12,188
Inventory	(4,098)	(3,388)
Other assets	10,593	(1,750)
Accounts payable	(401)	(4,200)
Accrued compensation	(120)	2,508
Accrued expenses	(465)	6,238
Accrued clinical trial expenses	1,247	1,468
Deferred revenue	(3,430)	(12,320)
Other liabilities	1,309	(2,681)
Net cash used in operating activities	(82,380)	(71,528)
Cash flows from investing activities:
Purchases of investments	(126,609)	(627,529)
Restricted cash	(25,000)
Maturities of investments	202,768	290,810
Sales of investments	5,378	218,660
Purchases of property and equipment	(5,744)	(8,294)
Net cash provided by (used in) investing activities	50,793	(126,353)
Cash flows from financing activities:
Payments of loan and capital lease obligations	(1,773)	(1,431)
Proceeds from issuance of senior secured notes, net of $4.4 million of issuance costs	78,006
Repayment of convertible subordinated notes	(172,407)
Proceeds from sale of future royalties, net of $4.4 million of transaction costs	119,588
Issuance of common stock, net of issuance costs	3,177	224,072
Net cash provided by financing activities	26,591	222,641
Effect of exchange rates on cash and cash equivalents	22	493
Net (decrease) increase in cash and cash equivalents	(4,974)	25,253
Cash and cash equivalents at beginning of period	15,312	17,755
Cash and cash equivalents at end of period	10,338	43,008
Supplemental disclosure of cash flows information:
Cash paid for interest	9,010	9,592
Retirement of convertible subordinate notes in exchange for senior secured notes	$ 42,548